Anti-BCMA Immuno-NanoPET Radiotracers for Improved Detection of Multiple Myeloma.

ABSTRACT: Current clinical imaging modalities for the sensitive and specific detection of multiple myeloma (MM) rely on nonspecific imaging contrast agents based on gadolinium chelates for magnetic resonance imaging (MRI) or for ¹⁸ F-FDG-directed and combined positron emission tomography (PET) and computed tomography (CT) scans. These tracers are not, however, able to detect minute plasma cell populations in the tumor niche, leading to false negative results. Here, a novel PET-based anti-BCMA nanoplatform labeled with ⁶⁴ Cu is developed to improve the monitoring of these cells in both the spine and femur and to compare its sensitivity and specificity to more conventional immunoPET (⁶⁴ Cu labeled anti-BCMA antibody) and passively targeted PET radiotracers (⁶⁴

SUBMITTER: Thomas E 

PROVIDER: S-EPMC11469021 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature